Semaglutide API prices plunge on GLP-1 demand surge

TL;DR

Semaglutide API prices have fallen sharply due to surging global demand for GLP-1 weight-loss drugs and patent expiry.
Synthetic prices dropped from $900 per gram three years ago to $90-$160 now, with recombinant at nearly $50 per gram.
This boosts affordability of generics from Indian firms, with prices set to drop another 20-30% soon.

The story at a glance

Surging demand for Novo Nordisk's Ozempic and Wegovy, plus their generics, has driven down semaglutide API prices despite broader pharma input cost pressures. Indian drugmakers like Sun Pharmaceuticals, Torrent, Dr Reddy's Laboratories, Natco, Eris, and Zydus have launched lower-priced generics after the patent expired on March 20, 2026. The story is reported now amid rapid manufacturing scale-up in China and recent off-patent moves in key markets.

Key points

Semaglutide API is mainly imported from China, with suppliers like Sinopep-Allsino Biopharmaceuticals; Indian firms like MSN are expanding production.
Synthetic semaglutide prices fell from $900/gram three years ago to $90-$160/gram; recombinant variants hit nearly $50/gram, with some reports of $50-60/gram for both.
Prices expected to soften further by 20-30% in coming months due to volume gains from patent expiry.
Chinese manufacturers have built multi-tonne capacity, outpacing demand and achieving cost efficiencies at scale.
Novo Nordisk's semaglutide patent expired on March 20, 2026, enabling generics in India and other markets.

Details and context

Global demand for GLP-1 drugs like Ozempic and Wegovy has spurred massive manufacturing expansion, especially in China, leading to oversupply and price drops for the API. This contrasts with rising costs for other pharma inputs from geopolitical issues, but semaglutide benefits from optimized production.

Indian generics are priced far below originators, improving access to weight-loss and diabetes treatments. The shift favors volume over high margins, a common API pattern as scale kicks in.

Key quotes

"Rapid surge in the global demand for weight-loss drug semaglutide has resulted in a significant drop in the prices of the semaglutide API that is mainly imported from China," said a top industry executive.[[1]](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/semaglutide-api-price-plunges-amid-glp-1-rush/articleshow/130317198.cms)[[2]](https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/semaglutide-api-price-plunges-amid-glp-1-rush/articleshow/130317198.cms)
"The steep drop in semaglutide API prices is largely driven by massive capacity build-up in China, where multi-tonne scale production has significantly outpaced demand growth," said Vishal Manchanda, pharma analyst at Systematix Group.[[1]](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/semaglutide-api-price-plunges-amid-glp-1-rush/articleshow/130317198.cms)

Why it matters

Lower API prices make GLP-1 therapies more affordable worldwide, expanding access for diabetes and obesity treatment amid high demand. Indian generic makers and consumers gain from cheaper drugs, while suppliers shift to volume-based profits; investors eye cost pressures elsewhere in pharma. Watch for further price drops and new generic launches, though rising input costs could temper gains.